NPPB and pulmonary arterial hypertension: A post hoc analysis from the GRIPHON study, a double-blind randomized placebo-controlled phase III study that assessed the safety and efficacy of selexipag in patients with PAH, established the prognostic relevance of NT-proBNP levels and their association with treatment response [38].